参考文献/References:
[1] Kanis JA. Assessment of osteoporosis at the primary health care level[R].Geneva:WHO Scientific Group Technical Report,2007.
[2] Strom O, Borgstrom F, Kanis JA, et al. Osteoporosis: burden, health care provision and opportunities in the EU: a report prepared in collaboration with the international osteoporosis foundation(IOF)and the european federation of pharmaceutical industry associations(EFPIA)[J]. Arch Osteoporos,2011, 6(1-2): 59-155.
[3] Harvey N, Dennison E, Cooper C. Osteoporosis: impact on health and economics[J]. Nat Rev Rheumatol,2010,6(2): 99-105.
[4] Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future[J]. Lancet,2011,377: 1276-1287.
[5] Mundy GR, Elefteriou F. Boning up on ephrin signaling[J].Cell,2006,126(3): 441-443.
[6] Khosla S. Minireview: the OPG/RANKL/RANK system[J]. Endocrinology,2001,142(12): 5050-5055.
[7] Tokuyama N, Tanaka S.Cytokines in bone diseases:genetic disorders of RANKL-RANK-OPG system[J]. Clin Calcium,2010,20(10): 1532-1538.
[8] Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density[J]. Cell,1997,89(2): 309-319.
[9] Tsuda E, Goto M, Mochizuki S, et al. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis[J]. Biochem Biophys Res Commun,1997,234(1): 137-142.
[10] 王信, 罗艳, 廖文波. 骨保护素体外抑制小鼠单核巨噬细胞成熟分化的实验研究[J].中国骨质疏松杂志,2013,19(3): 247-250.
[11] Makihira S, Mine Y, Nikawa H, et al. Immobilized-OPG-Fc on a titanium surface inhibits RANKL-dependent osteoclast differentiation in vitro[J]. J Mater Sci Mater Med,2010,21(2): 647-653.
[12] Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density[J]. Cell,1997,89(2): 309-319.
[13] Yasuda H.Bone and bone related biochemical examinations:bone and collagen related metabolites,receptor activator of NF-kappaB ligand(RANKL)[J]. Clin Calcium,2006,16(6): 964-970.
[14] Wu Y, Liu J, Guo H, et al. Establishment of OPG transgenic mice and the effect of OPG on bone microarchitecture[J]. Int J Endocrinol,2013: 125932.
[15] Nakagawa N, Kinosaki M, Yamaguchi K, et al. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis[J]. Biochem Biophys Res Commun,1998,253(2): 395-400.
[16] Suda T, Takahashi N, Udagawa N,et al. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families[J]. Endocr Rev,1999,20(3): 345-357.
[17] Battaglino RA, Pham L, Morse LR, et al. NHA-oc/NHA2: a mitochondrial cation-proton antiporter selectively expressed in osteoclasts[J]. Bone,2008,42(1): 180-192.
[18] Hsu H, Lacey DL, Dunstan CR, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand[J]. Proc Natl Acad Sci USA,1999,96(7): 3540-3545.
[19] Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling[J].Arch Biochem Biophys,2008,473(2): 139-146.
[20] Tanaka S. Signaling axis in osteoclast biology and therapeutic targeting in the RANKL/RANK/OPG system[J]. Am J Nephrol,2007,27(5): 466-478.
[21] Cao J, Venton L, Sakata T,et al. Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice[J]. J Bone Miner Res,2003,18(2): 270-277.
[22] Yano K, Tsuda E, Washida N, et al. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis[J]. J Bone Miner Res,1999,14(4): 518-527.
[23] 赵梅,韩伟. Notch信号传导通路相关疾病的研究进展[J].生物化学与生物物理进展,2006,33(12):1154-1160.
[24] Fuwa TJ, Hori K, Sasamura T, et al. The first deltex null mutantindicates tissue-specific deltex-dependent Notch signaling in Drosophila[J]. Mol Genet Genomics, 2006, 275(3):251-263.
[25] Gordon WR, Arnett KL, Blacklow SC. The molecular logic of Notch signaling-a structural and biochemical perspective[J]. J Cell Sci,2008,121(Pt 19): 3109-3119.
[26] Yamada T, Yamazaki H, Yamane T, et al. Regulation of osteoclast development by Notch signaling directed to osteoclast precursors and through stromal cells[J]. Blood,2003,101(6): 2227-2234.
[27] Boyce BF,Xing L.Biology of RANK,RANKL,andosteoprotegerin[J].Arthritis Res Ther,2007,9:S1.
[28] Yang X,Halladay D,Onyia JE,et aLProtein Kinase C is amediator of the synthesis and secretion of osteoprotegerin inosteoblast-like ceIIs[J].Biochem Bioph Res Commun,2002,290(1):42-46.
[29] Laceymunne DL,Tan HL,Liu I,et al.Osteoprotegerin ligand modulates osteoclast survival in nitro and in vivo[J].Am J Pathol,2000,157(2):435-448.
[30] 黎彦龙.OPG-RANKL-RANK信号系统是调节破骨细胞及骨质疏松症的重要算途径[J].中国组织工程研究,2015(06):3896.
[31] 孔祥鹤,牛银波,李宇华,等.OPG-RANKL-RANK系统与骨质疏松研究最新进展[J].生命科学研究,2011,15(1):80-85.
[32] Joseph DJ,Ichikawa S,Econs MJ.Mosaicism in osteopathia striata with cranial sclerosis[J]. J Clin Endocrinol Metab,2010,95(4):1506-1507.
[33] 仲蕾蕾,杨冰,黄晓斌,等.OPG/RANKL/RANK系统在成骨细胞和破骨细胞相互调节中的作用[J].中国骨质疏松杂志,2011,17(11): 1010-1013.
[34] Kulkarni RN,BakkerAD,Everts V,et al.lnhibition of osteoclastogenesis by mechanically loaded osteocytes: involvement of MEPE[J].Caleif Tissue Int,2010,87(5): 461-468
[35] Bai S, Kopan R, Zou W, et al. NOTCH1 regulates osteoclastogenesis directly in osteoclast precursors and indirectly via osteoblast lineage cells[J]. J Biol Chem,2008,283(10): 6509-6518.
[36] Duan L, de Vos P, Fan M,et al. Notch is activated in RANKL-induced osteoclast differentiation and resorption[J]. Front Biosci,2008,13: 7064-7071.
[37] Matsuo K, Irie N. Osteoclast-osteoblast communication[J]. Arch Biochem Biophys,2008,473(2): 201-209.
[38] Engin F, Bertin T, Ma O, et al. Notch signaling contributes to the pathogenesis of human osteosarcomas[J]. Hum Mol Genet,2009,18(8): 1464-1470.